JP2007514637A5 - - Google Patents

Download PDF

Info

Publication number
JP2007514637A5
JP2007514637A5 JP2006516317A JP2006516317A JP2007514637A5 JP 2007514637 A5 JP2007514637 A5 JP 2007514637A5 JP 2006516317 A JP2006516317 A JP 2006516317A JP 2006516317 A JP2006516317 A JP 2006516317A JP 2007514637 A5 JP2007514637 A5 JP 2007514637A5
Authority
JP
Japan
Prior art keywords
disorders
alcoholism
treatment
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006516317A
Other languages
English (en)
Japanese (ja)
Other versions
JP4783729B2 (ja
JP2007514637A (ja
Filing date
Publication date
Priority claimed from FR0307698A external-priority patent/FR2856683A1/fr
Application filed filed Critical
Publication of JP2007514637A publication Critical patent/JP2007514637A/ja
Publication of JP2007514637A5 publication Critical patent/JP2007514637A5/ja
Application granted granted Critical
Publication of JP4783729B2 publication Critical patent/JP4783729B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006516317A 2003-06-25 2004-06-24 ４−シアノピラゾール−３−カルボキシアミド誘導体、それらの製造法およびｃｂ１カンナビノイドアンタゴニストとしての用途 Expired - Fee Related JP4783729B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR03/07698 2003-06-25
FR0307698A FR2856683A1 (fr) 2003-06-25 2003-06-25 Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
PCT/FR2004/001580 WO2005000820A2 (fr) 2003-06-25 2004-06-24 Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application comme antagonistes des recepteurs aux cannabinoides cb1

Publications (3)

Publication Number Publication Date
JP2007514637A JP2007514637A (ja) 2007-06-07
JP2007514637A5 true JP2007514637A5 (https=) 2007-08-30
JP4783729B2 JP4783729B2 (ja) 2011-09-28

Family

ID=33515414

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006516317A Expired - Fee Related JP4783729B2 (ja) 2003-06-25 2004-06-24 ４−シアノピラゾール−３−カルボキシアミド誘導体、それらの製造法およびｃｂ１カンナビノイドアンタゴニストとしての用途

Country Status (9)

Country Link
US (2) US7282516B2 (https=)
EP (1) EP1641763B1 (https=)
JP (1) JP4783729B2 (https=)
AR (1) AR044874A1 (https=)
AT (1) ATE441635T1 (https=)
DE (1) DE602004022946D1 (https=)
FR (1) FR2856683A1 (https=)
TW (1) TW200510327A (https=)
WO (1) WO2005000820A2 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
FR2856683A1 (fr) * 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
US8853205B2 (en) 2005-01-10 2014-10-07 University Of Connecticut Heteropyrrole analogs acting on cannabinoid receptors
JP2008526887A (ja) * 2005-01-10 2008-07-24 ユニバーシティ オブ コネチカット カンナビノイド受容体に作用する新規なヘテロピロール類似体
FR2882365B1 (fr) * 2005-02-21 2007-09-07 Sanofi Aventis Sa Derives de 2-(1,5-diphenyl-1h-pyrazol-3-yl)-1,3,4-oxadiazole leur preparation et leur application en therapeutique
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
FR2887550A1 (fr) * 2005-06-24 2006-12-29 Sanofi Aventis Sa Derives de 1-benzylpyrazole-3-acetamide, leur preparation et leur application en therapeutique
FR2888236B1 (fr) * 2005-07-08 2007-09-21 Sanofi Aventis Sa Derives de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique
GB0514738D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Therapeutic agents
WO2007106721A2 (en) * 2006-03-10 2007-09-20 Jenrin Discovery Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
US7786144B2 (en) * 2006-05-31 2010-08-31 Solvay Pharmaceuticals B.V. Sulphur containing pyrazole derivatives as selective cannabinoid CB1 receptor antagonists
EP1878723B1 (fr) * 2006-07-11 2010-05-26 Sanofi-Aventis Dérivés de N-[(1,5-diphényl-1H-pyrazol-3-yl)méthyl]sulfonamide antagonistes des récepteurs CB1 des cannabinoïdes
US7297710B1 (en) 2006-07-12 2007-11-20 Sanofi-Aventis Derivatives of N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide, their preparation and their application in therapeutics
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
FR2908766B1 (fr) * 2006-11-20 2009-01-09 Sanofi Aventis Sa Derives de pyrrole,leur preparation et leur utilisation en therapeutique.
CA2673177A1 (en) 2006-12-18 2008-06-26 7Tm Pharma A/S Modulators of cb1 receptors
FR2911136B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique.
US7705024B2 (en) 2007-04-12 2010-04-27 National Health Research Institutes Oxadiazole compounds
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8133904B2 (en) * 2007-09-07 2012-03-13 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
EP2231615A1 (en) * 2007-12-10 2010-09-29 7TM Pharma A/S Cannabinoid receptor modulators
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
US10053444B2 (en) 2009-02-19 2018-08-21 University Of Connecticut Cannabinergic nitrate esters and related analogs
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CA3125847A1 (en) 2020-07-27 2022-01-27 Makscientific, Llc Process for making biologically active compounds and intermediates thereof
US12054480B2 (en) 2020-07-31 2024-08-06 Makscientific, Llc Compounds for treating cannabinoid toxicity and acute cannabinoid overdose

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2741621B1 (fr) * 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2856683A1 (fr) * 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique

Similar Documents

Publication Publication Date Title
JP2007514637A5 (https=)
JP2007522094A5 (https=)
JP2010534236A5 (https=)
CL2007001131A1 (es) Compuestos derivados de purina sustituida; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias.
JP2007514005A5 (https=)
JP2003503454A5 (https=)
WO2009064417A3 (en) Compositions for the treatment of gastrointestinal inflammation
HUE046110T2 (hu) Gyógyászati készítmények a rheumatoid arthritis betegségének és tüneteinek kezelésére
JP2009513660A5 (https=)
CL2007001132A1 (es) Compuestos derivados de purina sustituida con otros sistemas heterociclicos; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias.
JP2007536277A5 (https=)
GB0520751D0 (en) Pharmaceutical compositions for the treatment of chronic obstructive pulmonary disease
JP2010525055A5 (https=)
JP2009537554A5 (https=)
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
JP2007520565A5 (https=)
JP2005519891A5 (https=)
JP2009538898A5 (https=)
JP2008513510A5 (https=)
JP2010500284A5 (https=)
IL181240A0 (en) Use of cell-specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract
JP2008515980A5 (https=)
JP2007063263A5 (https=)
NO20054180D0 (no) Behandling av bakterielle sykdommer i andedrettsorganene ved lokal tilforsel av fluorkinoloner
JP2009091362A5 (https=)